Integrated Biopharma Files 8-K on Financials

TL;DR

IBP filed an 8-K on Nov 13th detailing financial condition. Check it out.

AI Summary

Integrated Biopharma, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition as of November 13, 2024. The filing includes financial statements and exhibits, with the company's principal executive offices located in Hillside, NJ.

Why It Matters

This 8-K filing provides crucial updates on Integrated Biopharma's financial performance and operational status, which is essential for investors to assess the company's current health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing (8-K) and does not contain new material events or significant changes.

Key Numbers

• 001-31668 — SEC File Number (Identifies the company's filing history with the SEC.)
• 22-2407475 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• INTEGRATED BIOPHARMA INC (company) — Registrant
• November 13, 2024 (date) — Date of earliest event reported
• November 14, 2024 (date) — Filing date
• 225 LONG AVENUE (address) — Business and mailing address
• HILLSIDE, NJ 07205 (address) — Business and mailing address

FAQ

Filing Documents

• inbp20241112_8k.htm (8-K) — 42KB
• ex_746768.htm (EX-99.1) — 43KB
• ibp_logo.jpg (GRAPHIC) — 12KB
• 0001437749-24-035331.txt ( ) — 226KB
• inbp-20241113.xsd (EX-101.SCH) — 3KB
• inbp-20241113_def.xml (EX-101.DEF) — 10KB
• inbp-20241113_lab.xml (EX-101.LAB) — 14KB
• inbp-20241113_pre.xml (EX-101.PRE) — 10KB
• inbp20241112_8k_htm.xml (XML) — 2KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On November 13, 2024, Integrated Biopharma, Inc. (the "Company") issued a press release announcing its financial results for its fiscal quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 2.02. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release dated November 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -1- EXHIBIT INDEX Exhibit Description 99.1 Press Release dated November 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INTEGRATED BIOPHARMA, INC. Date: November 14, 2024 By: /s/ Dina L Masi Dina L Masi Chief Financial Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR